Brain Metastases, Metastatic Rectal Adenocarcinoma
Conditions
Brief summary
A single arm observational study investigating the incidence of brain metastasis in patients with cancer recti and lung metastasis
Detailed description
In this study the investigators want to investigate the incidence of brain metastasis in a selected high-risk group of patients with metastatic colorectal cancer. Possible prognostic biological aspects will be investigated by translational analysis of biological samples. The study population consists of patients with metastatic rectal cancer and presence of lung metastasis. The patients will undergo a standard MRI scan of the brain including injection of intravenous contrast. If positive finding, images will be evaluated at the multidisciplinary tumor board for potential treatment options according to clinical practice. Standard follow-up program is followed, as per clinical practice. If the initial MRI scan of cerebrum detects brain metastasis this will be treated and followed as per clinical practice. Translational blood samples will be drawn at inclusion and at every imaging schedule up til 5 times
Interventions
None listed
Sponsors
Aarhus University Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Primary rectal tumor location * Diagnosis of lung metastasis made by histo- or cytopathology, or by clinical and imaging criteria. * Able to understand written information * Consent to samples for translational research
Exclusion criteria
* Contraindications for MRI Priorly treated or known brain metastases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of brain metastasis | 2 years | Incidence of brain metastasis in a high risk selected group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of brain metastases eligible for local treatment options | 2 years | Number of brain metastases eligible for local treatment options |
| Median two year overall survival | 2 years last patient | Median two year overall survival |
| Prognostic value of circulating DNA levels at baseline | 2 years last patient | — |
| Descriptive biological analysis of tumor tissue and circulating tumor DNA | 2 years last patient | — |
Countries
Denmark
Outcome results
None listed